Patheon extends Toronto facility for oral contraceptives production
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, has added 10,000sq ft to its Toronto manufacturing facility for the production of oral contraceptives with a potential output of 1.3 billion tablets.
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, has added 10,000sq ft to its Toronto manufacturing facility for the production of oral contraceptives with a potential output of 1.3 billion tablets.
This includes dispensing, granulation, compression, film coating and primary packaging. The new area will use abatement technology to eliminate solvent emissions.
Patheon will free up manufacturing capacity in the Toronto facility for current and new commercial business and allow for future growth within the pharmaceutical development services area. The newly expanded Toronto site will be a Centre of Excellence for oral contraceptives under Patheon's proprietary Quick to Clinic programme.
Terry Novak, president of Patheon North America said: "This expansion positions Patheon to compete on a higher level for contract manufacturing opportunities and claim a larger portion of the global oral contraceptive manufacturing market."